Biotech News
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
- Live video webcast on...
Open original release
Related news
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
ANABAnaptysBio, Inc.2026-05-04 20:15 EST
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
AVTXAvalo Therapeutics2026-07-22 11:00 EST
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
KYMRKymera2026-05-27 11:00 EST
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
BMYBMYBristol-Myers Squibb Company2026-05-27 10:59 EST
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
BMYBMYBristol-Myers Squibb Company2026-05-06 10:59 EST
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
NRIXNurix Therapeutics2026-04-07 11:00 EST
Nurix Therapeutics to Participate in Upcoming Investor Conference
KNSAKiniksa2026-05-29 20:01 EST
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
KYMRKymera2026-05-15 11:00 EST
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
GRI Bio
BioRestorative or GRI is a historical small-cap biotech entry tied to biologics and regenerative or related platform work. Its story is best understood as an early-stage development attempt rather than a mature commercial franchise.
Recent company news
GRIGRI Bio2026-06-18 13:31 EST
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GRIGRI Bio2026-05-14 08:35 EST
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
GRIGRI Bio2026-04-08 08:30 EST
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
GRIGRI Bio2026-02-17 09:15 EST
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor "What This Means" Segment
GRIGRI Bio2026-02-05 09:15 EST
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Stock data
- Close
- 1.40 USD
- Market cap
- 3.56M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States